QUIDELORTHO CORP Share-based Payment Arrangement, Expense
QUIDELORTHO CORP (QDEL) reported Share-based Payment Arrangement, Expense of $12.00 million for the 3-month period ending 2026-06-28, per its 10-Q filed 2026-08-07.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-08-07
- QUIDELORTHO CORP share-based payment arrangement, expense for the quarter ending 2026-06-28 was $12.00M, a 6.25% decline year-over-year.
- QUIDELORTHO CORP share-based payment arrangement, expense for the quarter ending 2026-03-29 was $10.70M, a 3.60% decline year-over-year.
- QUIDELORTHO CORP share-based payment arrangement, expense for the quarter ending 2025-12-28 was $10.80M, a 12.50% increase year-over-year.
- QUIDELORTHO CORP share-based payment arrangement, expense for the quarter ending 2025-09-28 was $10.80M, a 13.60% decline year-over-year.
- QUIDELORTHO CORP share-based payment arrangement, expense for fiscal 2025 was $45.50M, a 7.31% increase from fiscal 2024.
- QUIDELORTHO CORP share-based payment arrangement, expense for fiscal 2024 was $42.40M, a 33.54% decline from fiscal 2023.
- QUIDELORTHO CORP share-based payment arrangement, expense for fiscal 2023 was $63.80M, a 2.74% decline from fiscal 2023.
- QUIDELORTHO CORP share-based payment arrangement, expense for fiscal 2023 was $65.60M, a 158.27% increase from fiscal 2022.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 12 month |
|---|---|---|---|---|
| 2026-06-28 | $12.00M 10-Q · filed 2026-08-07 | $22.70M 10-Q · filed 2026-08-07 | $33.50M derived: sum of 3 quarters · filed 2026-08-07 | $44.30M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-29 | $10.70M 10-Q · filed 2026-05-06 | $21.50M derived: sum of 2 quarters · filed 2026-05-06 | $32.30M derived: sum of 3 quarters · filed 2026-05-06 | $45.10M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-28 | $10.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $21.60M derived: sum of 2 quarters · filed 2026-02-19 | $34.40M derived: sum of 3 quarters · filed 2026-08-07 | $45.50M 10-K · filed 2026-02-19 |
| 2025-09-28 | $10.80M 10-Q · filed 2025-11-06 | $23.60M derived: sum of 2 quarters · filed 2026-08-07 | $34.70M 10-Q · filed 2025-11-06 | $44.30M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-29 | $12.80M 10-Q · filed 2026-08-07 | $23.90M 10-Q · filed 2026-08-07 | $33.50M derived: sum of 3 quarters · filed 2026-08-07 | $46.00M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-30 | $11.10M 10-Q · filed 2026-05-06 | $20.70M derived: sum of 2 quarters · filed 2026-05-06 | $33.20M derived: sum of 3 quarters · filed 2026-05-06 | $44.40M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-29 | $9.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $22.10M derived: sum of 2 quarters · filed 2026-02-19 | $33.30M derived: sum of 3 quarters · filed 2026-02-19 | $42.40M 10-K · filed 2026-02-19 |
| 2024-09-29 | $12.50M 10-Q · filed 2025-11-06 | $23.70M derived: sum of 2 quarters · filed 2025-11-06 | $32.80M 10-Q · filed 2025-11-06 | $48.50M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-06-30 | $11.20M 10-Q · filed 2025-08-06 | $20.30M 10-Q · filed 2025-08-06 | $36.00M derived: sum of 3 quarters · filed 2026-02-19 | $53.10M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-03-31 | $9.10M 10-Q · filed 2025-05-08 | $24.80M derived: sum of 2 quarters · filed 2026-02-19 | $41.90M derived: sum of 3 quarters · filed 2026-02-19 | $58.90M derived: sum of 4 quarters · filed 2026-02-19 |
| 2023-12-31 | $15.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $32.80M derived: sum of 2 quarters · filed 2026-02-19 | $49.80M derived: sum of 3 quarters · filed 2026-02-19 | $63.80M 10-K · filed 2026-02-19 |
| 2023-10-01 | $17.10M 10-Q · filed 2024-11-08 | $34.10M derived: sum of 2 quarters · filed 2024-11-08 | $48.10M 10-Q · filed 2024-11-08 | $63.20M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-07-02 | $17.00M 10-Q · filed 2024-08-01 | $31.00M 10-Q · filed 2024-08-01 | $46.10M derived: sum of 3 quarters · filed 2025-02-27 | $62.30M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-04-02 | $14.00M 10-Q · filed 2024-05-09 | $29.10M derived: sum of 2 quarters · filed 2025-02-27 | $45.30M derived: sum of 3 quarters · filed 2025-02-27 | $61.20M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-01-01 | $15.10M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $31.30M derived: sum of 2 quarters · filed 2025-02-27 | $47.20M derived: sum of 3 quarters · filed 2025-02-27 | $65.60M 10-K · filed 2025-02-27 |
| 2022-10-02 | $16.20M 10-Q · filed 2023-11-02 | $32.10M derived: sum of 2 quarters · filed 2023-11-02 | $50.50M 10-Q · filed 2023-11-02 | $46.20M derived: sum of 4 quarters · filed 2024-08-01 |
| 2022-07-03 | $15.90M 10-Q · filed 2023-08-09 | $23.30M 10-Q · filed 2023-08-09 | $30.00M derived: sum of 3 quarters · filed 2024-08-01 | $37.00M derived: sum of 4 quarters · filed 2024-08-01 |
| 2022-04-03 | $7.40M 10-Q · filed 2023-05-04 | $14.10M derived: sum of 2 quarters · filed 2024-08-01 | $21.10M derived: sum of 3 quarters · filed 2024-08-01 | $26.90M derived: sum of 4 quarters · filed 2024-08-01 |
| 2022-01-02 | $6.70M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-08-01 | $13.70M derived: sum of 2 quarters · filed 2024-08-01 | $19.50M derived: sum of 3 quarters · filed 2024-08-01 | $25.40M 10-K/A · filed 2024-08-01 |
| 2021-10-03 | $7.00M 10-Q · filed 2022-11-04 | $12.80M derived: sum of 2 quarters · filed 2022-11-04 | $18.70M 10-Q · filed 2022-11-04 | |
| 2021-07-04 | $5.80M 10-Q · filed 2022-08-05 | $11.70M 10-Q · filed 2022-08-05 | ||
| 2021-01-03 | $21.00M 10-K · filed 2023-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |